Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
orexin receptor antagonist |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
491769-25-6
|
| gptkbp:chemicalFormula |
C30H23ClN6O3
|
| gptkbp:developedBy |
gptkb:Actelion
|
| gptkbp:discontinued |
safety concerns
|
| https://www.w3.org/2000/01/rdf-schema#label |
Almorexant
|
| gptkbp:intendedUse |
treatment of insomnia
|
| gptkbp:IUPACName |
2-[(2S,5R)-5-(4-chlorophenyl)-7-(2-methoxybenzyl)-4,5-dihydro-1,3-oxazol-2-yl]-N-[(2R)-2-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)butan-2-yl]acetamide
|
| gptkbp:legalStatus |
not approved
|
| gptkbp:mechanismOfAction |
dual orexin receptor antagonist
|
| gptkbp:molecularWeight |
551.99 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103837
9933476 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
development discontinued
|
| gptkbp:synonym |
ACT-078573
|
| gptkbp:target |
orexin-1 receptor
orexin-2 receptor |
| gptkbp:UNII |
2XJ0XK4C2V
|
| gptkbp:bfsParent |
gptkb:459789-99-2
|
| gptkbp:bfsLayer |
7
|